Serologic and immunologic markers in the course of HIV-1 infection (Q36527120)

14 August 2017

1 reference

title

Serologic and immunologic markers in the course of HIV-1 infection (English)

1 reference

14 August 2017

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

28 October 2022

author name string

de Wolf F

1

1 reference

14 August 2017

F. de Wolf

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1682023

28 October 2022

J. M. Lange

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1682023

28 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1682023

28 October 2022

publication date

1 January 1991

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:0738081X91901107?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

https://api.elsevier.com/content/article/PII:0738081X91901107?httpAccept=text/plain

28 October 2022

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

28 October 2022

published in

Clinics in Dermatology

1 reference

14 August 2017

volume

9

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

1-11

1 reference

A model-based estimate of the mean incubation period for AIDS in homosexual men

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Follow-up at 41/2 years on homosexual men with generalized lymphadenopathy.

28 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members

28 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study

28 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Lymphadenopathy syndrome in homosexual men. Evidence for continuing risk of developing the acquired immunodeficiency syndrome

28 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort

28 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: reappraisal of risk and predictive factors

28 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Incubation period of AIDS in San Francisco

28 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Incubation period of AIDS in patients infected via blood transfusion.

28 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Incubation periods for paediatric AIDS patients

28 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

28 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

RISK OF AIDS AFTER HERPES ZOSTER

28 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome

28 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS.

28 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Lymphadenopathy in asymptomatic patients seropositive for HIV.

28 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Primary human T-lymphotropic virus type III infection

28 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion

28 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HTLV-III infection associated with glandular-fever-like illness in a haemophiliac

28 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Clinical picture of primary HIV infection presenting as a glandular-fever-like illness

28 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Acute encephalopathy coincident with seroconversion for anti-HTLV-III.

28 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III.

28 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HTLV-III and vacuolar myelopathy

28 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Acute myelopathy associated with primary infection with human immunodeficiency virus

28 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HIV antigenaemia and virus isolation from plasma during primary HIV infection

28 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection

28 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HIV isolation from plasma of HIV-infected persons

28 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection

28 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs

28 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antigen detection in primary HIV infection

28 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Early diagnosis of HIV infection in the neonate

28 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Delayed and defective anti-HIV IgM response in infants

28 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibody response to human immunodeficiency virus after primary infection

28 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibody response in primary human immunodeficiency virus infection

28 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis

28 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibodies to the Core Protein of Lymphadenopathy-Associated Virus (LAV) in Patients with AIDS

28 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS.

28 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients

28 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus

28 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus

28 October 2022

55

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Patterns of antibody response in individuals infected with the human immunodeficiency virus

28 October 2022

56

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Correlation of enzyme-linked immunosorbent assays for serum human immunodeficiency virus antigen and antibodies to recombinant viral proteins with subsequent clinical outcomes in a cohort of asymptomatic homosexual men.

28 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression

28 October 2022

59

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection.

28 October 2022

60

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance

28 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men.

28 October 2022

63

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Appearance of predictors of disease progression in relation to the development of AIDS.

28 October 2022

65

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men

28 October 2022

66

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy

28 October 2022

67

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Predictors of AIDS in homosexual men

28 October 2022

68

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Clinical and biological features in the 12 months preceding onset of AIDS in HIV-infected subjects

28 October 2022

70

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients

28 October 2022

72

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection

28 October 2022

74

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Intra-blood-brain barrier synthesis of human immunodeficiency virus antigen and antibody in humans and chimpanzees

28 October 2022

75

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Expression of human immunodeficiency virus in cerebrospinal fluid of children with progressive encephalopathy

28 October 2022

76

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Human immunodeficiency virus type 1 antigen in cerebrospinal fluid. Correlation with clinical neurologic status

28 October 2022

77

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

A preliminary evaluation of five HIV antigen detection assays

28 October 2022

78

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Human immunodeficiency virus antigenemia in patients with AIDS and AIDS-related disorders: a comparison between European and Central African populations

28 October 2022

80

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Transfusion-acquired human immunodeficiency virus infection among immunocompromised persons

28 October 2022

81

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases.

28 October 2022

82

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study

28 October 2022

84

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection

28 October 2022

85

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibody response to human immunodeficiency virus type 1 protease according to risk group and disease stage

28 October 2022

86

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts

28 October 2022

87

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibody response to a synthetic peptide covering a LAV-1/HTLV-IIIB neutralization epitope and disease progression.

28 October 2022

88

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibody response to the viral negative factor (nef) in HIV-1 infection

28 October 2022

89

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects

28 October 2022

91

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS

28 October 2022

92

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583-599), do not correlate significantly with outcome in HIV infection.

28 October 2022

93

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity

28 October 2022

94

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

High prevalence of serum antibodies to reverse transcriptase in HIV-1-infected individuals

28 October 2022

95

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

28 October 2022

97

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

28 October 2022

98

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Decline in CD4+ cell numbers reflects increase in HIV-1 replication

28 October 2022

99

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus

28 October 2022

100

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Immunological changes in lymphadenopathy virus positive and negative symptomless male homosexuals: two years of observation

28 October 2022

101

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Four-year prospective study of homosexual men: correlation of immunologic abnormalities, clinical status, and serology to human immunodeficiency virus

28 October 2022

102

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age.

28 October 2022

103

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Progressive cellular immune impairment leading to development of AIDS: two-year prospective study of HIV infection in drug addicts

28 October 2022

106

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Prognostic usefulness of the Walter Reed staging classification for HIV infection

28 October 2022

108

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Functional versus phenotypic analysis of T cells in subjects seropositive for the human immunodeficiency virus: a prospective study of in vitro responses to Cryptococcus neoformans

28 October 2022

114

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Patients at risk for AIDS-related opportunistic infections. Clinical manifestations and impaired gamma interferon production.

28 October 2022

115

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HIV transmission through kidney transplantation from a living related donor

28 October 2022

119

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serum 2 -microglobulin in renal disease.

28 October 2022

131

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Elevation of serum β2 microglobulin in liver diseases

28 October 2022

132

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Plasma and urinary levels of beta2 microglobulin in rheumatoid arthritis

28 October 2022

133

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serum beta 2-microglobulin in malignant lymphoma

28 October 2022

134

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases

28 October 2022

135

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Elevation of serum beta 2-microglobulin levels during infectious mononucleosis

28 October 2022

136

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serum beta 2-microglobulin and C reactive protein concentrations in viral infections

28 October 2022

137

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome

28 October 2022

139

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serum beta-2 microglobulin levels in homosexual men with AIDS and with persistent, generalized lymphadenopathy.

28 October 2022

140

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations

28 October 2022

142

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection

28 October 2022

143

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Predicting who will progress to AIDS.

28 October 2022

144

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine

28 October 2022

145

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

28 October 2022

146

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

CSF and serum beta-2-microglobulin in HIV infection related to neurological dysfunction

28 October 2022

154

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Neopterin as a marker for activated cell-mediated immunity: application in HIV infection

28 October 2022

155

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

28 October 2022

158

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Neopterin levels correlating with the Walter Reed staging classification in human immunodeficiency virus (HIV) infection

28 October 2022

159

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Neopterin and beta 2-microglobulin as markers for AIDS

28 October 2022

161

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1.

28 October 2022

162

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

From persistent generalised lymphadenopathy to AIDS: who will progress?

28 October 2022

165

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Disseminated Kaposi's sarcoma in homosexual men.

28 October 2022

168

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Increased frequency of HLA-DR5 in lymphadenopathy stage of AIDS

28 October 2022

170

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection

28 October 2022

171

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease

28 October 2022

172

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HLA antigens are risk factors for development of AIDS

28 October 2022

174

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

HLA haplotype and HIV infection

28 October 2022

176

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study

28 October 2022

177

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Human immunodeficiency virus viremia as a prognostic indicator in homosexual men with lymphadenopathy syndrome

28 October 2022

178

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Measurement of human immunodeficiency virus load and its relation to disease progression

28 October 2022

179

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Serial determinations of HIV-1 titers in HIV-infected homosexual men: association of rising titers with CD4 T cell depletion and progression to AIDS.

28 October 2022

180

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Quantitation of human immunodeficiency virus type 1 in the blood of infected persons

28 October 2022

181

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Efficient isolation of HIV from plasma during different stages of HIV infection

28 October 2022

182

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Plasma viremia in human immunodeficiency virus infection

28 October 2022

183

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Biologic features of HIV-1 that correlate with virulence in the host

28 October 2022

185

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates

28 October 2022

186

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality

28 October 2022

187

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency.

28 October 2022

190

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Humoral immune responses to T cell tropic retrovirus simian T lymphotropic virus type III in monkeys with experimentally induced acquired immune deficiency-like syndrome

28 October 2022

193

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Natural history of HIV infection

28 October 2022

194

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

Analysis of absolute T helper cell number and cellular immune defects in HIV antibody positive and negative homosexual men

28 October 2022

195

1 reference

https://api.crossref.org/works/10.1016/0738-081X(91)90110-7

28 October 2022

Identifiers

1 reference

14 August 2017

1 reference